ARS Pharmaceuticals (SPRY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.63
- Estimate
- -$0.49
- Surprise
- -27.7%
- Revenue (period 2026-06-30)
- $33.7M
- Score today
- 6.0/10
Revenue source: xbrl.
How the report landed
ARS Pharmaceuticals (SPRY) reported a wider loss than forecast — adjusted EPS of -$0.63 against the -$0.49 estimate (a 27.7% shortfall).
Coverage in the report window
- Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s — benzinga, 2026-08-14
- Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket — benzinga, 2026-08-14
- ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates SPRY Hold at 6.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -27.7% surprise compares with a -2.5% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: neffy
- DATA_ISSUE: analyst_target_implausible (raw $24.33 vs price $3.65 — ratio 6.7×). Rejected, falling back to technical TP.
- Market cap $363M below $400M minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.65
- Price target
- $4.54
- Stop
- $3.41
- Upside to target
- +24.4%
Risk check: RSI 27 — a level conventionally read as oversold; trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
SPRY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $363.0M
- P/E (fwd)
- -4.1
- 52-week range
- $3.52–$13.15
- Off 52-week high
- 72.2%
- RSI (14)
- 27
- Volume vs avg
- 1.54×
- Score today
- 6.0/10